Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Yannis Metaxas, MD, Cantonal Hospital Grison, Chur, Switzerland, discusses the results from the phase I part of the phase I/II SAKK 57/16 trial (NCT03524898). This study investigated nab-paclitaxel and gemcitabine in soft tissue sarcoma.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.